Evidence record · ER-ELAMIPRETIDE-BARTH-017
Does elamipretide improve muscle strength in Barth syndrome?
Forzinity (elamipretide) improves muscle strength in people with Barth syndrome who weigh at least 30 kg
US-authorised Forzinity (elamipretide) is supported for improving knee extensor muscle strength in people with Barth syndrome who weigh at least 30 kg. The FDA used accelerated approval, and confirmatory evidence is required. This narrow finding does not support anti-ageing, general mitochondrial or athletic-performance claims.
Claim boundary
What this verdict covers
The supported claim is the exact US accelerated-approval indication and surrogate endpoint. It does not apply to other mitochondrial conditions, lower-weight patients, healthy people or unverified peptide products.
- Compound
- Elamipretide
- Population
- People with Barth syndrome weighing at least 30 kg
- Outcome
- Knee extensor muscle strength
- Record ID
- ER-ELAMIPRETIDE-BARTH-017
Evidence synthesis
What the research can support
The blinded crossover trial missed its prespecified primary endpoints, while open-label extension and natural-history analyses supplied later muscle-strength signals. FDA granted accelerated approval in 2025 for the narrow population and requires a confirmatory trial.
Why the confidence is moderate
Accelerated approval reflects residual uncertainty. The confirmatory study must verify clinical benefit, and US authorisation is not UK authorisation.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-ELAMIPRETIDE-BARTH-017 addresses one bounded question: Does elamipretide improve muscle strength in Barth syndrome?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human and regulator, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| TAZPOWER phase 2/3 trial | The blinded crossover did not meet its primary endpoints; extension data generated additional signals. | The trial alone did not establish a broad mitochondrial benefit. | 10 August 2026 |
| FDA Forzinity accelerated-approval letter | FDA authorised a narrow Barth-syndrome indication and required confirmatory evidence. | The letter does not create a UK authorisation. | 10 August 2026 |
| US Forzinity prescribing information | The label defines the population, endpoint, warnings and use conditions. | It does not support anti-ageing or healthy-performance use. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Elamipretide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
The blinded crossover trial missed its prespecified primary endpoints, while open-label extension and natural-history analyses supplied later muscle-strength signals. FDA granted accelerated approval in 2025 for the narrow population and requires a confirmatory trial. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Elamipretide authorised in the UK for this use?
Elamipretide received US accelerated approval for a narrow Barth-syndrome indication in September 2025. No UK marketing authorisation was identified; the US decision does not transfer jurisdictions. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Elamipretide is not specifically named on the 2026 WADA Prohibited List. Athletes should still check current rules and any therapeutic-use requirements. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
Completion of the FDA-required confirmatory trial, a full-approval decision, UK regulatory assessment or material new safety evidence. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation